Literature DB >> 24771945

Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility.

P Sinn1, S Aulmann1, R Wirtz2, S Schott3, F Marmé3, Z Varga4, A Lebeau5, H Kreipe6, A Schneeweiss7.   

Abstract

Gene signatures which are based on multigene profiling assays have been developed for the purpose to better define the prognosis and prediction of therapy results in early-stage breast cancer. These assays were designed to be more specific than conventional clinico-pathologic parameters in the selection of patients for (neo-)adjuvant treatment and in effect help to avoid unnecessary cytotoxic treatment. In this review we describe molecular risk scores, for which tests are commercially available (PAM50®, MammaTyper®, MammaPrint®, Oncotype DX®, Endopredict®, Genomic Grade Index®) and IHC risk scores (Mammostrat® and IHC4), and discuss the current evidence of their clinical use.

Entities:  

Keywords:  breast cancer; multigene assays; prognosis

Year:  2013        PMID： 24771945      PMCID： PMC3859151          DOI： 10.1055/s-0033-1350831

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN： 0016-5751            Impact factor:   2.915


  85 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement.

Authors:  H A Azim; S Michiels; F Zagouri; S Delaloge; M Filipits; M Namer; P Neven; W F Symmans; A Thompson; F André; S Loi; C Swanton
Journal:  Ann Oncol       Date:  2013-01-20       Impact factor: 32.976

3.  Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour.

Authors:  Zeinab Elsawaf; Hans-Peter Sinn; Joachim Rom; Justo Lorenzo Bermejo; Andreas Schneeweiss; Sebastian Aulmann
Journal:  Breast       Date:  2013-06-24       Impact factor: 4.380

4.  Challenges translating breast cancer gene signatures into the clinic.

Authors:  Britta Weigelt; Lajos Pusztai; Alan Ashworth; Jorge S Reis-Filho
Journal:  Nat Rev Clin Oncol       Date:  2011-08-30       Impact factor: 66.675

5.  Comparison of the effect of different techniques for measurement of Ki67 proliferation on reproducibility and prognosis prediction accuracy in breast cancer.

Authors:  Einar Gudlaugsson; Ivar Skaland; Emiel A M Janssen; Rune Smaaland; Zhiming Shao; Anais Malpica; Feja Voorhorst; Jan P A Baak
Journal:  Histopathology       Date:  2012-09-11       Impact factor: 5.087

6.  Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.

Authors:  Ben S Wittner; Dennis C Sgroi; Paula D Ryan; Tako J Bruinsma; Annuska M Glas; Anitha Male; Sonika Dahiya; Karleen Habin; Rene Bernards; Daniel A Haber; Laura J Van't Veer; Sridhar Ramaswamy
Journal:  Clin Cancer Res       Date:  2008-05-15       Impact factor: 12.531

7.  Histological grading of breast carcinomas: a study of interobserver agreement.

Authors:  P Robbins; S Pinder; N de Klerk; H Dawkins; J Harvey; G Sterrett; I Ellis; C Elston
Journal:  Hum Pathol       Date:  1995-08       Impact factor: 3.466

8.  HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.

Authors:  George Fountzilas; Christos Valavanis; Vassiliki Kotoula; Anastasia G Eleftheraki; Konstantine T Kalogeras; Olympia Tzaida; Anna Batistatou; Ralf Kronenwett; Ralph M Wirtz; Mattheos Bobos; Eleni Timotheadou; Nikolaos Soupos; George Pentheroudakis; Helen Gogas; Dimitrios Vlachodimitropoulos; Genovefa Polychronidou; Gerasimos Aravantinos; Angelos Koutras; Christos Christodoulou; Dimitrios Pectasides; Petroula Arapantoni
Journal:  J Transl Med       Date:  2012-01-12       Impact factor: 5.531

9.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

Authors:  R Peto; C Davies; J Godwin; R Gray; H C Pan; M Clarke; D Cutter; S Darby; P McGale; C Taylor; Y C Wang; J Bergh; A Di Leo; K Albain; S Swain; M Piccart; K Pritchard
Journal:  Lancet       Date:  2011-12-05       Impact factor: 79.321

10.  PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer.

Authors:  Miguel Martín; Aleix Prat; Alvaro Rodríguez-Lescure; Rosalía Caballero; Mark T W Ebbert; Blanca Munárriz; Manuel Ruiz-Borrego; Roy R L Bastien; Carmen Crespo; Carole Davis; César A Rodríguez; José M López-Vega; Vicente Furió; Ana M García; Maribel Casas; Matthew J Ellis; Donald A Berry; Brandelyn N Pitcher; Lyndsay Harris; Amparo Ruiz; Eric Winer; Clifford Hudis; Inge J Stijleman; David P Tuck; Eva Carrasco; Charles M Perou; Philip S Bernard
Journal:  Breast Cancer Res Treat       Date:  2013-02-20       Impact factor: 4.872
View more
  29 in total

Review 1.  [Molecular pathology for breast cancer: Importance of the gene expression profile].

Authors:  C Denkert; B M Pfitzner; B I Heppner; M Dietel
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

2.  Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study.

Authors:  P A Fasching; T Fehm; S Kellner; J de Waal; M Rezai; B Baier; G Baake; H-C Kolberg; M Guggenberger; M Warm; N Harbeck; R Würstlein; J-U Deuker; P Dall; B Richter; G Wachsmann; C Brucker; J W Siebers; N Fersis; T Kuhn; C Wolf; H-W Vollert; G-P Breitbach; W Janni; R Landthaler; A Kohls; D Rezek; T Noesslet; G Fischer; S Henschen; T Praetz; V Heyl; T Kühn; T Krauß; C Thomssen; S Kümmel; A Hohn; H Tesch; C Mundhenke; A Hein; C Rauh; C M Bayer; A Jacob; K Schmidt; E Belleville; P Hadji; D Wallwiener; E-M Grischke; M W Beckmann; S Y Brucker
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-12       Impact factor: 2.915

3.  Transplantation: Molecular diagnosis of kidney transplant rejection.

Authors:  Christian Morath; Martin Zeier
Journal:  Nat Rev Nephrol       Date:  2014-06-17       Impact factor: 28.314

4.  Breast Cancer Update 2014 - Focus on the Patient and the Tumour.

Authors:  N Maass; F Schütz; P A Fasching; T Fehm; W Janni; S Kümmel; H-C Kolberg; D Lüftner; M Wallwiener; M P Lux
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-02       Impact factor: 2.915

5.  Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.

Authors:  Umar Wazir; Kefah Mokbel
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer.

Authors:  A Kümmel; S Kümmel; J Barinoff; F Heitz; J Holtschmidt; W Weikel; F Lorenz-Salehi; A du Bois; P Harter; A Traut; J U Blohmer; B Ataseven
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-07       Impact factor: 2.915

Review 7.  Molecular Genomic Testing for Breast Cancer: Utility for Surgeons.

Authors:  Oluwadamilola M Fayanju; Ko Un Park; Anthony Lucci
Journal:  Ann Surg Oncol       Date:  2017-11-20       Impact factor: 5.344

Review 8.  [Metastatic breast cancer in the spine : Molecular predictors for choosing adequate treatment strategies].

Authors:  D Adler; M Kriegsmann; P Sinn; A Schneeweiss; H Almansour; B Lehner; M Akbar
Journal:  Orthopade       Date:  2018-07       Impact factor: 1.087

9.  Trastuzumab Administration in Patients with Metastatic Breast Cancer - Experience of a Large University Breast Center.

Authors:  A D Hartkopf; M H Brendel; M Wallwiener; F-A Taran; S Brucker; E-M Grischke
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-06       Impact factor: 2.915

10.  ICG Fluorescence Technique for the Detection of Sentinel Lymph Nodes in Breast Cancer: Results of a Prospective Open-label Clinical Trial.

Authors:  E-M Grischke; C Röhm; M Hahn; G Helms; S Brucker; D Wallwiener
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.